济人药业IPO申请获北交所受理，系疏风解毒胶囊生产商

Group 1 - The core viewpoint of the news is that Anhui Jiren Pharmaceutical Co., Ltd. has had its IPO application accepted by the Beijing Stock Exchange, marking a significant step in its growth as a modern traditional Chinese medicine enterprise [1][2]. - Jiren Pharmaceutical's main products include traditional Chinese medicine (TCM) preparations, TCM pieces, and TCM formula granules, with its core product being the Shufeng Jiedu capsule, which is included in treatment plans for various diseases [1]. - The company was established in April 2001 and has developed into a comprehensive TCM pharmaceutical enterprise that integrates standardized planting of medicinal materials, production, and sales [1]. Group 2 - For its IPO, Jiren Pharmaceutical has chosen the first listing standard of the Beijing Stock Exchange, which requires a market value of no less than 200 million yuan and net profits of at least 15 million yuan in the last two years [2]. - The company plans to raise approximately 526 million yuan, which will be used for projects including the annual production of 450 tons of TCM formula granules and 8,000 tons of TCM pieces, as well as for research and development and marketing network construction [2]. - The IPO is sponsored by Guojin Securities, with Daixin Accounting Firm serving as the auditing firm [3].